ReviewJournal of neuro-oncology2003
Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses.
Review in Journal of neuro-oncology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 90 citations in OpenAlex.
- Article
- Biodegradable brain-penetrating DNA nanocomplexes and their use to treat malignant brain tumors.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Review
- Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.Nanomedicine (London, England) · 2016Review
- A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy.Molecular biotechnology · 2015Article
- Gene therapy for malignant glioma.Molecular and cellular therapies · 2014Review
- Therapeutic nanomedicine for brain cancer.Therapeutic delivery · 2013Review
- MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.Journal of neuro-oncology · 2013Article
- Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.Human gene therapy · 2012Article
- Therapeutic strategies for head and neck cancer based on p53 status.Experimental and therapeutic medicine · 2012Article
- Gene therapy and targeted toxins for glioma.Current gene therapy · 2011Review
- An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.Gene therapy · 2010Article
- Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells.Neuro-oncology · 2010Article
- RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses.Cancer gene therapy · 2009Article
- Stem cells as delivery vehicles for oncolytic adenoviral virotherapy.Current gene therapy · 2009Review
- Gene- and viral-based therapies for brain tumors.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009Article
- Adenoviral virotherapy for malignant brain tumors.Expert opinion on biological therapy · 2009Review
- Ligand-directed cancer gene therapy to angiogenic vasculature.Advances in genetics · 2009Review
- Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.Gene therapy · 2008Article
- Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.Neurosurgical review · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoviruses have been critical in the development of the molecular approaches to brain tumors. They have been engineered to function as vectors for delivering therapeutic genes in gene therapy strategies, and as direct cytotoxic agents in oncolytic viral therapies. This review outlines the uses of adenoviruses in brain tumor therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of two conditionally replicative adenoviruses (CRAds) ONYX-015 and Delta 24 in brain tumors. The potential clinical use of CRAds that deliver trangenes, particularly p53, is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.